Synthetic Biology Market By Tool (Oligonucleotides and Synthetic DNA, Enzymes), By Application (Medical Application, Pharmaceuticals, Drug Discovery and Therapeutics), By Technology (Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics), By Region - Industry Forecast 2026-2033

Synthetic Biology Market size was valued at USD 17.8 Billion in 2024 and is poised to grow from USD 22.34 Billion in 2025 to USD 137.47 Billion by 2033, growing at a CAGR of 25.5% during the forecast period (2026–2033).

Key vendors in the Synthetic Biology Market include Ginkgo Bioworks Holdings Inc., Twist Bioscience Corporation, Amyris Inc., Codexis Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Zymergen Inc., Synthego Corporation, New England Biolabs Inc., and Precigen Inc.. These companies focus on gene synthesis, genome engineering, synthetic DNA technologies, bio-based product development, and advanced biotechnology platforms serving healthcare, agriculture, industrial biotechnology, and environmental applications globally.

The key driver of the Synthetic Biology Market is the increasing demand for advanced genetic engineering and bio-based solutions across healthcare, agriculture, and industrial applications. Rising investments in biotechnology research, growing adoption of gene editing technologies, and the need for sustainable production methods for pharmaceuticals, chemicals, and biofuels are significantly driving market growth globally.

The key market trend in the Synthetic Biology Market is the growing integration of artificial intelligence, automation, and gene-editing technologies to accelerate biological design and development. Companies are increasingly leveraging platforms such as CRISPR, synthetic DNA synthesis, and bioengineering tools to develop customized therapeutics, sustainable bio-based products, and next-generation industrial biotechnology solutions, driving innovation across multiple sectors globally.

North America accounted for the largest share in the Synthetic Biology Market due to strong investments in biotechnology research, the presence of leading synthetic biology companies, and advanced healthcare and research infrastructure. Increasing adoption of gene-editing technologies, supportive government funding, and growing demand for bio-based innovations further support regional market dominance.